130.06
0.13%
-0.17
Dopo l'orario di chiusura:
129.49
-0.57
-0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Merck & Co Inc Borsa (MRK) Ultime notizie
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
Zacks Investment Research
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Zacks Investment Research
Jim Cramer Advises Investors To Brace For Economic Slowdown, Shares Tips To Maintain Balanced Portfolio: 'I'm Not Telling You To Relax'
Benzinga
A Look at Pharma ETFs Post Q1 Earnings
Zacks Investment Research
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Zacks Investment Research
SCHD: A Must-Have In Every Dividend Portfolio
Seeking Alpha
Here's Why Merck (MRK) is a Strong Momentum Stock
Zacks Investment Research
Job Market Cools In April: Payrolls Miss Forecasts, Wages Rise Less Than Expected (UPDATED)
Benzinga
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks Investment Research
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks Investment Research
Merck Shines in Q1 2024 Earnings Surge
The Motley Fool
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks Investment Research
Merck (MRK) Q1 2024 Earnings Call Transcript
The Motley Fool
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Zacks Investment Research
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Benzinga
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks Investment Research
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Zacks Investment Research
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Benzinga
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
Zacks Investment Research
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Zacks Investment Research
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Zacks Investment Research
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Zacks Investment Research
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks Investment Research
Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS
Zacks Investment Research
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Benzinga
Wall Street Breakfast: The Week Ahead
Seeking Alpha
Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline
Zacks Investment Research
Unveiling 17 Analyst Insights On Merck & Co
Benzinga
Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth
Zacks Investment Research
Merck (MRK) Advances While Market Declines: Some Information for Investors
Zacks Investment Research
Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel
Zacks Investment Research
Better Growth Play: Merck or The Vanguard Growth Index Fund?
The Motley Fool
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.
The Motley Fool
1 New Green Flag for Moderna and Merck Stock
The Motley Fool
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
Zacks Investment Research
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
Benzinga
Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study
Zacks Investment Research
Company News for Apr 10, 2024
Zacks Investment Research
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
Zacks Investment Research
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
Zacks Investment Research
2 Dividend Stocks to Buy and Hold Forever
The Motley Fool
Down 75%. Is Agenus Stock a Buy on the Dip?
The Motley Fool
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Zacks Investment Research
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
Zacks Investment Research
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
Zacks Investment Research
Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate
Zacks Investment Research
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
Zacks Investment Research
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
Zacks Investment Research
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug
Zacks Investment Research
Capitalizzazione:
|
Volume (24 ore):